A new study has been published in MDPI, the scholarly open access publishing journal, using GlycoCheck. The study also includes citations from GlycoCheck Co-Founder and Chief Science Officer, Dr. Hans Vink.
The study is titled “May We Use Non-Invasive Indices of Aortic Stiffness and Endothelial Glycocalyx as Biomarkers for Idiopathic Pulmonary Artery Hypertension Follow-Up?” from the Departments of Cardiology and Critical Care from National and Kapodistrian University of Athens, Greece.
Study Abstract
Idiopathic pulmonary arterial hypertension (IPAH) initial evaluation and follow-up, a rare and incurable disease if left untreated, is based on a multiparametric approach (functional status of the patient, biomarkers, hemodynamic parameters and imaging evaluation of right heart impairment). Arterial stiffness (AS) and endothelial glycocalyx are indices of systemic circulation. We present the 3-years follow-up of a female IPAH patient. We propose aortic stiffness and endothelial glycocalyx indices as non-invasive markers of either improvement or deterioration of IPAH disease.
This study is one of 74 using GlycoCheck. All 74 studies can be reviewed on GlycoCheck.com. The Aortic Stiffness and Endothelial Glycocalyx can be directly accessed here.
GlycoCheck Software Update
The new patented GlycoCheck 5.2 software is complete, has been fully tested and used in some new peer-reviewed published papers. The new software offers a significant upgrade to the MicroVascular Health Score™. The software adds new algorithms to measure red cell velocity in the smallest capillaries, determines the flow dependency of capillary density and glycocalyx properties, and calculates an overall Microvascular Health Score based on 100 million measurements of red cell column width in 100,000 vessels segments. We’ve also introduced two completely new reports along with easy-to-understand graphs and gauges. The 5.2 version software is available for upgrade purchase by previous GlycoCheck owners. Contact us for more information.
